Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06459193

Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy

Peripheral Neuropathy Due to Chemotherapy Clinical Trial

Official title:
Evaluation of Trimetazidine in Alleviating Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients

Clinical Trial Summary

This proof-of-concept study evaluated the effect of Trimetazidine on the incidence of paclitaxel-induced peripheral neuropathy in patients with breast cancer.

Clinical Trial Description

Chemotherapy-induced peripheral neuropathy (CIPN) is a major adverse effect of many commonly used chemotherapeutic agents that greatly affect patient quality of life. Paclitaxel (PTX), one of the main neurotoxic classes of anticancer drugs, is used to treat several types of solid tumors, including breast cancer. Development of PTX-induced peripheral neuropathy (PIPN) during cancer treatment requires dose reduction limiting its clinical benefits. The only currently recognized prophylactic measure for chemotherapy-induced peripheral neuropathy (CIPN) is monitoring for pre-existing neuropathies and then the early detection of clinical symptoms of neuropathy in subjects undergoing neurotoxic chemotherapy treatment. Preclinical data has shown that the neuroprotective effect of trimetazidine (TMZ) can attenuate PIPN. TMZ has preclinical evidence about its preventive capacity against peripheral neuropathy. Which represents a possible prophylactic strategy for attenuating PIPN. TMZ is commercially available in various preparations that are relatively affordable and well-tolerated, making it a valid candidate for clinical evaluation. ;

Study Design

Related Conditions & MeSH terms

  • Peripheral Nervous System Diseases
  • Peripheral Neuropathy Due to Chemotherapy
Clinical Trial Details
NCT number NCT06459193
Study type Interventional
Source Minia University
Contact Asmaa Najm Iqbal Ahmed, Demonstrator
Phone +201091965003
Email asmaa.najm98@gmail.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date June 16, 2024
Completion date November 30, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05875610 - Preventive Approach Using Venlafaxine Phase 4
Not yet recruiting NCT06313359 - Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.
Recruiting NCT03571334 - Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy Phase 2
Completed NCT04461977 - Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer N/A
Recruiting NCT06135493 - Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients Phase 2
Completed NCT03492047 - N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients Phase 1/Phase 2